Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Incyte Corp (INCY) Q2 2020 Earnings Call Transcript | The Motley Fool
07:00pm, Tuesday, 04'th Aug 2020
INCY earnings call for the period ending June 30, 2020.
Incyte (INCY) Beats on Q2 Earnings and Sales on Strong Jakafi
02:10pm, Tuesday, 04'th Aug 2020
Incyte (INCY) easily surpasses earnings and sales expectations in the second quarter as lead drug, Jakafi, reports strong growth.
Dow Jones Today Dips, Nasdaq Fights To Extend Streak; Take-Two, SolarEdge, AMD Rocket
01:58pm, Tuesday, 04'th Aug 2020
Take-Two, Inphi and Incyte rallied Tuesday, but stock futures dipped as the Dow Jones looked toward Disney's after-hours report.
Incyte (INCY) Q2 Earnings and Revenues Beat Estimates
12:45pm, Tuesday, 04'th Aug 2020
Incyte (INCY) delivered earnings and revenue surprises of 61.04% and 15.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Incyte Corporation (INCY) CEO Hervé Hoppenot on Q2 2020 Results - Earnings Call Transcript
12:22pm, Tuesday, 04'th Aug 2020
Incyte Corporation (INCY) CEO Hervé Hoppenot on Q2 2020 Results - Earnings Call Transcript
Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
11:00am, Tuesday, 04'th Aug 2020
Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
Incyte (INCY) Beats on Q2 Earnings and Sales on Strong Jakafi
10:10am, Tuesday, 04'th Aug 2020
Incyte (INCY) easily surpasses earnings and sales expectations in the second quarter as lead drug, Jakafi, reports strong growth.
Incyte (INCY) Q2 Earnings and Revenues Beat Estimates
08:45am, Tuesday, 04'th Aug 2020
Incyte (INCY) delivered earnings and revenue surprises of 61.04% and 15.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Incyte Earnings Soar 65%, Easily Beating Views
07:41am, Tuesday, 04'th Aug 2020
Incyte earnings and revenue rose much more than expected. The biotech reaffirmed guidance.
Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
07:00am, Tuesday, 04'th Aug 2020
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #earnings--Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
12:00am, Tuesday, 04'th Aug 2020
Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
MorphoSys FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:MOR)
04:12pm, Monday, 03'rd Aug 2020
MorphoSys receives FDA approval for Monjuvi. Brigham president tenders resignation from Moderna board after conflict of interest.
Dow Jones Today, Stocks Rise As Microsoft Courts TikTok; Varian Soars On Siemens Deal; Incyte, Co-Diagnostics FDA News
01:55pm, Monday, 03'rd Aug 2020
Incyte paced the Nasdaq, Microsoft led the Dow Jones, and stock futures rose as global markets rallied on strong manufacturing data.
FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population
01:19pm, Monday, 03'rd Aug 2020
The FDA approved Monjuvi for second-line diffuse large B-cell lymphoma. Though the drug has the same antigen target as approved CAR-T cell therapies, it is designed for patients unable to tolerate suc
Is a Surprise Coming for Incyte (INCY) This Earnings Season?
12:38pm, Monday, 03'rd Aug 2020
Incyte (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
